Renamed Nastech Turns To RNAi
This article was originally published in The Pink Sheet Daily
Executive Summary
Company to divest intranasal program rather than spin out.
You may also be interested in...
AstraZeneca Will Validate siRNA Delivery Technology For MDRNA In Shanghai Innovation Center
SHANGHAI - Bothell, Washington-headquartered MDRNA announced recently that the company will collaborate with AstraZeneca to validate MDRNA's small interfering RNA (siRNA) technology for systemic delivery in hepatocellular carcinoma, one of the company's preclinical oncology programs
Novartis Extends RNAi Deal With Alnylam
Terms include another year and potential for more equity.
Novartis Extends RNAi Deal With Alnylam
Terms include another year and potential for more equity.